SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Oxford Biomedica, (OXB).
An SI Board Since June 2000
Posts SubjectMarks Bans
111 5 0
Emcee:  Oily1 Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
86Oxford, UK: 27 May 2004 - Oxford BioMedica (LSE:OXB.L), the leading gene therapyOily1-5/27/2004
85OXFORD BIOMEDICA GAINS FDA APPROVAL FOR A PHASE II TRIAL OF TROVAX(R) IN RENAL COily1-4/29/2004
84Annual General Meeting 2004. 20 April 2004 OXFORD BIOMEDICA ANNUAL GENERAL MEETOily1-4/20/2004
83OXFORD BIOMEDICA AWARDED £0.5 MILLION FROM THE UK DEPARTMENT OF HEALTHGENE Oily1-3/29/2004
82Final results for 2003 : oxfordbiomedica.co.ukOily1-3/3/2004
81RNS Number:0448V Oxford Biomedica PLC 05 February 2004 For immediate release Oily1-2/5/2004
80CRUK GIVEN APPROVAL TO START A PHASE II TRIAL WITH TROVAX(R) IN COLORECTAL CANCEOily1-1/16/2004
79OXFORD BIOMEDICA ONCOLOGY UPDATE RNS Number:4000T Oxford Biomedica PLC 18 DecemOily1-12/18/2003
78OXFORD BIOMEDICA PRESENTS PROOF-OF-PRINCIPLE DATA FOR ITS INNUREXTM NERVE REPAIROily1-12/15/2003
77Oxford Biomedica PLC - Research Update RNS Number:5497S Oxford Biomedica PLC 27 Oily1-11/27/2003
76BLOCK LISTING SIX MONTHLY RETURN To: Listing Applications Oily1-11/25/2003
75Oxford Biomedica PLC - Preclinical update RNS Number:9988R Oxford Biomedica PLC Oily1-11/13/2003
74Interview with Professor Kingsman on Wall Street Reporter. wallstreetreporter.cOily1-10/26/2003
735T4 newscientist.comOily1-10/25/2003
72RNS Number:2742R Oxford Biomedica PLC 24 October 2003 For immediate release 200Oily1-10/24/2003
71INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2003 Oxford, UK: 16 September Oily1-9/19/2003
70OXFORD BIOMEDICA AND ENTREMED ENTER AGREEMENT ON RETINOSTAT(TM) PROGRAMME OxforOily1-9/12/2003
69CANCER RESEARCH UK SUPPORTS ADDITIONAL TROVAX PHASE II TRIAL IN COLORECTAL CANCEOily1-8/28/2003
68Oxford Biomedica PLC - Notice of Results RNS Number:8478O Oxford Biomedica PLC 2Oily1-8/20/2003
6713/08/03 07:00: LentiVector Patent Update Oxford Biomedica PLC - LentiVector PaOily1-8/13/2003
66SECOND TROVAX PHASE I/II TRIAL RESULTS PRESENTED AT MEETING OF THE AMERICAN ASSOOily1-7/16/2003
65POSITIVE RESULTS FROM METXIA PHASE I/II BREAST CANCER TRIAL AND PLANS FOR Oily1-7/3/2003
64Oxford Biomedica PLC - Update on ProSavin RNS Number:6212M Oxford Biomedica PLC Oily1-6/23/2003
63Oxford BioMedica’s TroVax® Receives Clearance from the United States RecombOily1-6/3/2003
62Oxford Biomedica PLC - TroVax Update RNS Number:2657L Oxford Biomedica PLC 20 MaOily1-5/20/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News